Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:recombinant_factor_VIII
|
| gptkbp:administered_by |
intravenous injection
|
| gptkbp:approves |
gptkb:2003
gptkb:FDA |
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:contraindication |
hypersensitivity to components
|
| gptkbp:developed_by |
gptkb:Baxter_International
|
| gptkbp:dosage_form |
lyophilized powder
|
| https://www.w3.org/2000/01/rdf-schema#label |
octocog alfa
|
| gptkbp:ingredients |
factor VIII
|
| gptkbp:marketed_as |
Advate
|
| gptkbp:mechanism_of_action |
replaces deficient factor VIII
|
| gptkbp:side_effect |
headache
nausea infusion site reactions |
| gptkbp:storage |
refrigerated
|
| gptkbp:used_for |
gptkb:hemophilia_A
|
| gptkbp:bfsParent |
gptkb:Adynovate
|
| gptkbp:bfsLayer |
6
|